Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 186

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies

Open access
Chew, Hui Yi, De Lima, Priscila O., Gonzalez Cruz, Jazmina L., Banushi, Blerida, Echejoh, Godwins, Hu, Lingbo, Joseph, Shannon R., Lum, Benedict, Rae, James, O’Donnell, Jake S., Merida de Long, Lilia, Okano, Satomi, King, Brigid, Barry, Rachael, Moi, Davide, Mazzieri, Roberta, Thomas, Ranjeny, Souza-Fonseca-Guimaraes, Fernando, Foote, Matthew, McCluskey, Adam, Robinson, Phillip J., Frazer, Ian H., Saunders, Nicholas A., Parton, Robert G., Dolcetti, Riccardo, Cuff, Katharine, Martin, Jennifer H., Panizza, Benedict, Walpole, Euan, Wells, James W., Simpson, Fiona·2020·Cell

Abstract

A safe and controlled manipulation of endocytosis in vivo may have disruptive therapeutic potential. Here, we demonstrate that the anti-emetic/anti-psychotic prochlorperazine can be repurposed to reversibly inhibit the in vivo endocytosis of membrane proteins targeted by therapeutic monoclonal antibodies, as directly demonstrated by our human tumor ex vivo assay. Temporary endocytosis inhibition results in enhanced target availability and improved efficiency of natural killer cell-mediated antibody-dependent cellular cytotoxicity (ADCC), a mediator of clinical responses induced by IgG1 antibodies, demonstrated here for cetuximab, trastuzumab, and avelumab. Extensive analysis of downstream signaling pathways ruled out on-target toxicities. By overcoming the heterogeneity of drug target availability that frequently characterizes poorly responsive or resistant tumors, clinical application of reversible endocytosis inhibition may considerably improve the clinical benefit of ADCC-mediating therapeutic antibodies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cell.2020.02.019

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

Metadata

Authors
Chew, H. Y., De Lima, P. O., Gonzalez Cruz, J. L., Banushi, B., Echejoh, G., Hu, L., Joseph, S. R., Lum, B., Rae, J., O’Donnell, J. S., Merida de Long, L., Okano, S., King, B., Barry, R., Moi, D., Mazzieri, R., Thomas, R., Souza-Fonseca-Guimaraes, F., Foote, M., McCluskey, A., Robinson, P. J., Frazer, I. H., Saunders, N. A., Parton, R. G., Dolcetti, R., Cuff, K., Martin, J. H., Panizza, B., Walpole, E., Wells, J. W., & Simpson, F.
Venue
Cell
Publisher
Elsevier BV
Published
2020-03
Volume
180
Issue
5
Pages
895-914.e27
ISSN
0092-8674 (ISSN-L)
OpenAlex
W3010469101
Cited by
186
References
10
FWCI
12.10
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies. https://app.cochat.ai/papers/10.1016/j.cell.2020.02.019
The paper
Chew, H. Y., De Lima, P. O., Gonzalez Cruz, J. L., Banushi, B., Echejoh, G., Hu, L., Joseph, S. R., Lum, B., Rae, J., O’Donnell, J. S., Merida de Long, L., Okano, S., King, B., Barry, R., Moi, D., Mazzieri, R., Thomas, R., Souza-Fonseca-Guimaraes, F., Foote, M., . . . Simpson, F. (2020). Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies. Cell. https://doi.org/10.1016/j.cell.2020.02.019

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.